指南与共识垂体与肾上腺疾病

原发性醛固酮增多症:内分泌学会临床实践指南

Primary Aldosteronism: An Endocrine Society Clinical Practice Guideline.
指南 / 共识 · J Clin Endocrinol Metab · 2025-01-01

该指南由内分泌学会多学科专家组采用GRADE方法制定,针对10个关于原发性醛固酮增多症(PA)诊断和治疗的问题进行系统评价。指南建议所有高血压患者通过测定醛固酮和肾素并计算醛固酮肾素比值进行筛查,并根据结果指导后续诊疗;建议PA患者接受药物或手术治疗,并优先选择盐皮质激素受体拮抗剂(MRA)中的螺内酯。

要点

  • 所有高血压患者均应筛查PA,检测醛固酮和肾素并计算醛固酮肾素比值。
  • PA患者应接受针对性治疗,药物首选MRA,其中螺内酯因成本低、可及性高而优先。
  • 筛查阳性者根据侧别概率决定是否行醛固酮抑制试验及肾上腺静脉采血。

核心结论

  • 指南为PA的诊断和治疗提供了实用框架,旨在提高PA的识别率并通过针对性治疗改善血压控制和减少心血管事件。

研究设计与样本

  • 指南制定小组由多学科临床专家和系统评价方法学专家组成,采用GRADE方法定义10个关于PA诊断和治疗的问题,并对每个问题进行系统评价。

主要发现

  • 建议所有高血压患者通过测定醛固酮和肾素并计算醛固酮肾素比值进行PA筛查。
  • 建议PA患者接受针对性药物或手术治疗。
  • 对于筛查阳性者,若不适合或不愿手术且侧别概率低,建议开始针对性药物治疗;若侧别概率中等且患者愿意追求手术资格,建议行醛固酮抑制试验。
  • 对于抑制试验阳性或筛查显示侧别概率高者,建议在决定治疗前进行肾上腺CT和肾上腺静脉采血。
  • 所有PA伴肾上腺腺瘤者建议行1毫克过夜地塞米松抑制试验。

关键数值与推荐

  • 建议药物治疗PA时选择MRA而非ENaC抑制剂。
  • 建议优先选择螺内酯而非其他MRA,因其成本更低且可及性更高;但所有MRA在滴定至等效效力时预期疗效相似。
  • 接受MRA治疗者建议监测肾素,若高血压未控制且肾素受抑制,建议滴定MRA以升高肾素。

临床怎么用

  • 对所有高血压患者进行PA筛查,检测醛固酮和肾素并计算比值。
  • 根据筛查结果和患者意愿,选择药物治疗或手术,药物治疗首选MRA。
  • 使用MRA时监测肾素,指导剂量滴定。

局限性

  • 指南指出了PA诊断和管理中重要的知识空白。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Primary aldosteronism (PA), a primary adrenal disorder leading to excessive aldosterone production by one or both adrenal glands, is a common cause of hypertension. It is associated with an increased risk of cardiovascular complications compared with primary hypertension. Despite effective methods for diagnosing and treating PA, it remains markedly underdiagnosed and undertreated. OBJECTIVE: To develop an updated guideline that provides a practical, clinical approach to identifying and managing PA to improve diagnosis rates and encourage targeted treatment. METHODS: The Guideline Development Panel (GDP), composed of a multidisciplinary panel of clinical experts and experts in systemic review methodology, used the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) approach to define 10 questions related to the diagnosis and treatment of PA. Systematic reviews were conducted for each question. The GDP used the GRADE Evidence to Decision (EtD) framework to consider contextual factors, such as stakeholder values and preferences, costs and required resources, cost-effectiveness, acceptability, feasibility, and the potential impact on health equity. RESULTS: We suggest that all individuals with hypertension be screened for PA by measuring aldosterone and renin and determining the aldosterone to renin ratio, and that subsequent clinical care be guided by the results. We suggest that individuals with PA receive PA-specific therapy, either medical or surgical. In individuals who screen positive for PA, we suggest (1) commencement of PA-specific medical therapy in individuals who do not desire or are not candidates for surgery and in situations where the probability of lateralizing PA (excess aldosterone produced by one adrenal) is low based on screening results; and (2) aldosterone suppression testing in situations when screening results indicate an intermediate probability for lateralizing PA and individualized decision making confirms a desire to pursue eligibility for surgical therapy. In those who test positive by aldosterone suppression testing, and in those in whom screening results show a high probability of lateralizing PA (obviating the need for aldosterone suppression testing), we suggest adrenal lateralization with computed tomography scanning and adrenal venous sampling prior to deciding the treatment approach (medical vs surgical). In all individuals with PA and an adrenal adenoma, we suggest performing a 1-mg overnight dexamethasone suppression test. We suggest the use of mineralocorticoid receptor antagonists (MRAs) over epithelial sodium-channel (ENaC) inhibitors in the medical treatment of PA. We suggest the use of spironolactone over other MRAs, given its lower cost and greater availability; however, all MRAs, when titrated to equivalent potencies, are anticipated to have similar efficacy in treating PA. Thus, MRAs with greater mineralocorticoid receptor specificity and fewer androgen/progesterone receptor-mediated side effects may be preferred in some situations. In individuals receiving MRA therapy, we suggest monitoring renin and, in those whose hypertension remains uncontrolled and renin is suppressed, titrating the MRA to increase renin. CONCLUSION: These recommendations provide a practical framework for the diagnosis and treatment of PA. They are based on currently available literature and take into consideration outcomes that are important to key stakeholders. The goal is to increase identification of individuals with PA and, by initiating PA-specific medical or surgical therapy, improve blood pressure control and reduce PA-associated adverse cardiovascular events. The guidelines also highlight important knowledge gaps in PA diagnosis and management.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Adler GK, Stowasser M, Correa RR, et al. Primary Aldosteronism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2025. PMID: 40658480. doi:10.1210/clinem/dgaf284

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。